Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,203JPY
19 Jun 2018
Change (% chg)

¥-103 (-2.39%)
Prev Close
¥4,306
Open
¥4,262
Day's High
¥4,267
Day's Low
¥4,203
Volume
5,281,900
Avg. Vol
4,561,419
52-wk High
¥6,693
52-wk Low
¥4,203

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  4502.T Industry Sector
P/E (TTM): 30.36 30.95 32.75
EPS (TTM): 203.74 -- --
ROI: 5.07 14.84 14.38
ROE: 8.38 16.34 16.07

Deals of the day-Mergers and acquisitions

June 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

12 Jun 2018

Takeda shareholder group aims to block $62 billion Shire deal

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.

11 Jun 2018

Takeda shareholder group aims to block $62 billion Shire deal

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.

11 Jun 2018

UPDATE 1-Takeda shareholder group aims to block $62 bln Shire deal

* Owns 1 pct of shares, needs one third of shareholders to block

11 Jun 2018

Takeda shareholders group say working to block $62 bln Shire deal

TOKYO, June 11 A group of Takeda Pharmaceutical Co Ltd shareholders is building support to block the $62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.

11 Jun 2018

UPDATE 1-Shareholders demand Japan's Takeda assuage fears over Shire deal

* Proposal says Shire deal could damage existing shareholders

29 May 2018

CORRECTED-OFFICIAL-Shareholders demand Japan's Takeda assuage fears over Shire deal

TOKYO, May 29 Japanese drugmaker Takeda Pharmaceutical Co Ltd faces demands from disgruntled shareholders to put to a vote its $62-billion acquisition of London-listed Shire and do more to assuage concerns over the record-breaking deal.

29 May 2018

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

17 May 2018

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

17 May 2018

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

* Takeda boss to raise bar for pipeline drugs after Shire deal

17 May 2018

Earnings vs. Estimates